Kentucky Retirement Systems Insurance Trust Fund purchased a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 55,687 shares of the company's stock, valued at approximately $1,335,000.
Other institutional investors also recently modified their holdings of the company. SRS Capital Advisors Inc. grew its position in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after buying an additional 571 shares during the period. Clarity Asset Management Inc. acquired a new stake in shares of Kenvue during the 4th quarter worth approximately $45,000. SBI Securities Co. Ltd. bought a new position in Kenvue during the 4th quarter worth approximately $46,000. Deseret Mutual Benefit Administrators boosted its stake in Kenvue by 29.0% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock worth $54,000 after acquiring an additional 568 shares during the last quarter. Finally, Versant Capital Management Inc boosted its stake in Kenvue by 77.9% during the 1st quarter. Versant Capital Management Inc now owns 3,415 shares of the company's stock worth $82,000 after acquiring an additional 1,495 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Kenvue Stock Performance
Shares of KVUE opened at $21.39 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $25.17. The firm's 50 day moving average price is $22.99 and its two-hundred day moving average price is $22.40. The firm has a market cap of $41.03 billion, a P/E ratio of 38.88, a PEG ratio of 3.32 and a beta of 0.98.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The firm's revenue for the quarter was down 3.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.28 earnings per share. On average, analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.83%. The ex-dividend date was Wednesday, May 14th. Kenvue's dividend payout ratio is presently 149.09%.
Wall Street Analyst Weigh In
Several research firms recently weighed in on KVUE. UBS Group lifted their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Friday, May 9th. Redburn Atlantic began coverage on shares of Kenvue in a research note on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective on the stock. Barclays lifted their price objective on shares of Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research note on Monday, May 12th. Evercore ISI began coverage on shares of Kenvue in a research note on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective on the stock. Finally, Citigroup reissued a "neutral" rating on shares of Kenvue in a research note on Friday, June 13th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $25.33.
Get Our Latest Stock Report on Kenvue
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
